Retatrutide Pipeline and FDA Status: What Women Need to Know in 2025

What Is Retatrutide and Where Does It Stand With the FDA?

Retatrutide is not FDA-approved. No Drugs@FDA listing, no prescribing label, and no New Drug Application (NDA) decision date has been publicly announced as of July 2025. Eli Lilly has confirmed Phase 3 trials are enrolling, but the company has not filed for approval, which means no woman can legally receive retatrutide outside of a clinical trial.

What makes retatrutide different from semaglutide or tirzepatide is its third receptor target: glucagon. Adding glucagon receptor activity increases energy expenditure beyond what GLP-1 or GIP stimulation alone achieves. That additional mechanism is why the Phase 2 numbers are larger than anything seen with currently approved agents.

How the Triple-Agonist Mechanism Works

The GLP-1 component slows gastric emptying and reduces appetite. GIP enhances insulin sensitivity and may reduce nausea relative to pure GLP-1 agents. The glucagon component drives thermogenesis, meaning your resting metabolic rate increases even during caloric restriction. For women specifically, this thermogenic effect is worth watching closely, because estrogen already modulates energy expenditure and adipose distribution, and interactions between endogenous estrogen and glucagon signaling have not yet been characterized in humans in a sex-stratified way.

The Phase 2 Trial: What It Found

The key Phase 2 study by Jastreboff et al., published in the New England Journal of Medicine in July 2023, enrolled 338 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related complication. Participants were randomized to once-weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks.

At the highest dose (12 mg), mean weight loss reached 24.2% of body weight, far exceeding the approximately 15% seen with semaglutide 2.4 mg in the STEP 1 trial and the approximately 20.9% seen with tirzepatide 15 mg in SURMOUNT-1. At the 8 mg dose, mean weight loss was 22.8%. These are striking figures, and they have driven significant interest from women who have not achieved their goals on currently approved agents.

What Phase 3 Is Testing

Eli Lilly's Phase 3 program (TRIUMPH trials) is evaluating retatrutide in adults with obesity and, separately, adults with type 2 diabetes. The TRIUMPH-1 trial is testing 8 mg and 12 mg doses against placebo over 72 weeks. Cardiovascular outcome data are not yet available. As of this writing, no Phase 3 results have been published in peer-reviewed journals, and no interim data have been released.

Sex-Specific Physiology: What the Data Do and Do Not Tell Us

Women metabolize GLP-1 receptor agonists differently from men. Body composition, gastric emptying rate, sex-hormone-binding globulin levels, and estrogen-driven changes in fat distribution all affect how these drugs behave. Retatrutide is no exception, and the data gap here is real.

What Phase 2 Showed for Women

The Jastreboff et al. Phase 2 trial did include women. Approximately 54% of participants were female. Sex-stratified efficacy data were not reported as a primary or secondary outcome, and the published paper does not break out weight loss by sex. This is a meaningful limitation. We know that in the STEP 1 semaglutide trial, women lost slightly less weight than men as a percentage of body weight, a pattern also seen with tirzepatide in secondary analyses. Whether retatrutide follows the same pattern is unknown.

Menstrual Cycle and Hormonal Status

No published data characterize how retatrutide pharmacokinetics change across the menstrual cycle. With semaglutide, nausea tends to spike in the luteal phase when progesterone already slows gastric motility, and the same mechanism likely applies to retatrutide's GLP-1 component. Women in the follicular phase may tolerate dose escalation better than those in the luteal phase, though this has not been formally studied for any GLP-1-containing agent and certainly not for retatrutide.

Perimenopause and Menopause

During perimenopause, declining estrogen shifts fat storage from the periphery (hips and thighs) to visceral depots. Visceral adiposity is exactly the type that responds most to GLP-1 and glucagon receptor activation. This makes retatrutide a potentially strong candidate for perimenopausal and postmenopausal women, but no trial has enrolled participants stratified by menopausal stage. The TRIUMPH trials do not list menopausal status as a stratification variable in publicly available ClinicalTrials.gov records reviewed for this article. Women and their clinicians should not assume that the overall Phase 2 weight-loss figures apply equally to perimenopausal women on vasomotor symptom management.

PCOS

Women with polycystic ovary syndrome have insulin resistance as a core feature, and GLP-1 receptor agonists improve insulin sensitivity and can restore ovulatory cycles. GIP agonism may add further benefit. No retatrutide trial has specifically enrolled women with PCOS, but given the mechanism, it is biologically plausible that the drug would offer reproductive and metabolic benefits similar to or greater than those seen with semaglutide in PCOS populations. A 2023 randomized trial found semaglutide reduced BMI by 8.7% and improved menstrual regularity in women with PCOS over 12 weeks, a benchmark that retatrutide's more aggressive weight-loss profile might exceed, but this is extrapolation, not direct evidence.

Retatrutide Safety: What Is Known, What Is Not

Safety data from Phase 2 give the clearest window we have into what a retatrutide label might ultimately say. The full label will only exist after FDA review of Phase 3 data, which has not yet occurred.

Gastrointestinal Side Effects

The most common adverse events in Phase 2 were nausea, vomiting, diarrhea, and constipation, all consistent with GLP-1 receptor activation. In the 12 mg group, 42% of participants reported nausea and 20% reported vomiting. The majority of events were mild to moderate and occurred during dose escalation. Women are known to experience higher rates of GLP-1-induced nausea than men, likely because female baseline gastric emptying is slower and progesterone compounds that effect, so these figures may underestimate the rate women will experience in practice.

Gallbladder Events

Rapid weight loss increases biliary cholesterol saturation and gallstone risk. This is relevant for women, who develop gallstones at roughly twice the rate of men at baseline. Phase 2 did not show a markedly elevated gallbladder event rate, but the 48-week duration may be too short to fully capture this risk. Phase 3 and post-market surveillance will be critical here.

Heart Rate

Glucagon receptor agonism raises resting heart rate, and the retatrutide Phase 2 trial found mean heart rate increases of approximately 6 to 9 beats per minute at higher doses. Women in perimenopause already experience palpitations from estrogen fluctuation, and a superimposed chronotropic effect warrants attention in that population.

Thyroid C-Cell Concerns

Like all GLP-1 receptor agonists, retatrutide carries a theoretical thyroid C-cell tumor risk based on rodent data. No human signal has emerged in any GLP-1 agent's post-market surveillance to date, but the FDA mandates a black-box warning for this class. Retatrutide's label, when it exists, will almost certainly carry the same warning. Women with a personal or family history of medullary thyroid carcinoma or MEN2 should plan to avoid the drug.

Lean Mass Loss

Higher rates of weight loss can mean more lean muscle loss if protein intake and resistance exercise are not prioritized. Women over 50 are already at risk for sarcopenia, and the aggressive weight loss seen with retatrutide's higher doses may accelerate muscle loss in this group. This is a clinical concern without retatrutide-specific data yet.

Pregnancy, Lactation, and Contraception: A Required Conversation

Retatrutide is not approved, and no official pregnancy category exists. Based on the mechanism and the class behavior of GLP-1 receptor agonists, the following guidance is grounded in available science and regulatory precedent.

Pregnancy

GLP-1 receptor agonists as a class are associated with fetal harm in animal studies. The FDA has required pregnancy exclusions in all GLP-1 and dual-agonist trials to date. Semaglutide's label states it should be discontinued at least 2 months before a planned pregnancy due to embryofetal toxicity in animal studies. Tirzepatide's label carries a similar requirement. When retatrutide receives a label, it will almost certainly include the same or longer washout recommendation given its triple-receptor mechanism and longer-duration investigation.

Women of reproductive age enrolled in the TRIUMPH Phase 3 trials are required to use highly effective contraception throughout treatment, consistent with standard GLP-1 trial protocols. If you are trying to conceive, retatrutide is not appropriate even within a trial setting unless you are willing to delay attempts until a safe washout period after discontinuation.

No human pregnancy exposure data for retatrutide exist. Any pregnancy occurring during trial participation is tracked in safety databases but does not yet inform a public dataset.

Lactation

No data on retatrutide transfer into human breast milk exist. GLP-1 receptor agonists are large peptide molecules and are unlikely to transfer in clinically significant amounts, but this has not been studied for retatrutide specifically. Until human lactation pharmacokinetic data are available, women who are breastfeeding should not use retatrutide outside of a clinical trial, and trial protocols typically exclude breastfeeding participants.

Contraception Interactions

GLP-1 receptor agonists slow gastric emptying, which can theoretically reduce absorption of oral contraceptive pills, particularly during dose escalation. The FDA label for semaglutide oral tablets (Rybelsus) recommends taking oral contraceptives at least 30 minutes before the dose or 4 hours after. For injectable forms, the interaction is less clinically significant, but it has not been ruled out for retatrutide specifically. Women relying on oral contraception during any retatrutide trial participation should discuss timing with their prescribing clinician.

Who Retatrutide May Be Right For (and Who Should Wait)

No clinician can prescribe retatrutide today. This section is forward-looking, based on the Phase 2 population and mechanism.

Women Who May Be Strong Candidates

Women with a BMI of 30 or higher, or a BMI of 27 or higher with a related condition such as type 2 diabetes, hypertension, or sleep apnea, who have not achieved their goals with currently approved agents are the primary target population. Given the visceral fat reduction potential, perimenopausal and postmenopausal women with metabolic syndrome and women with PCOS and significant insulin resistance represent biologically plausible strong-responder groups, though this is not yet confirmed by direct evidence.

Women Who Should Not Use It

Women who are pregnant, planning pregnancy, or breastfeeding should not use retatrutide. Women with a personal or family history of medullary thyroid carcinoma or MEN2 fall outside the expected indication based on class precedent. Women with a prior history of pancreatitis warrant careful discussion given the GLP-1 component's association with that risk.

Women in the reproductive years who are not using reliable contraception should not enroll in retatrutide trials until they have established an effective contraceptive method and discussed the washout period required before any conception attempt.

The Regulatory Road Ahead: What an FDA Label Might Contain

Based on regulatory precedent for semaglutide (Wegovy, approved June 2021) and tirzepatide (Zepbound, approved November 2023), a retatrutide label will likely include the following elements, though none of this is confirmed until an NDA is filed and reviewed.

Expected Label Sections

A black-box warning for thyroid C-cell tumors is standard for the class. Contraindications will almost certainly include pregnancy and personal or family history of medullary thyroid carcinoma or MEN2. Warnings will cover pancreatitis, gallbladder disease, hypoglycemia in patients taking insulin or sulfonylureas, heart rate increases, and suicidal ideation (required by FDA for obesity medications since the lorcaserin era, though the clinical signal for GLP-1 agents has not materialized).

REMS Likelihood

The FDA did not require a Risk Evaluation and Mitigation Strategy (REMS) for semaglutide or tirzepatide beyond standard label warnings. Retatrutide is unlikely to require one unless Phase 3 or post-market data reveal an unexpected safety signal.

Likely Indication Language

Based on the SURMOUNT and STEP trials as precedent, expect language along the lines of: "as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 or higher, or 27 or higher in the presence of at least one weight-related comorbidity." Women-specific language on contraception requirements and pregnancy avoidance will appear in Sections 4 (Contraindications), 5.x (Warnings), and 8 (Use in Specific Populations) of the label.

Post-Market Surveillance Requirements

The FDA consistently requires post-market cardiovascular outcome trials for obesity drugs. For retatrutide, a CVOT is expected as a post-approval commitment. Eli Lilly's ongoing cardiovascular trial infrastructure from the SURPASS program may be adapted. Sex-stratified and menopausal-status-stratified analyses in post-market studies would address the evidence gap that currently exists in Phase 2 data, but these sub-analyses depend on how study populations are designed and whether FDA requests them as part of the label supplement process.

Evidence Gaps Women Should Know About

Six gaps matter most for female patients and the clinicians caring for them.

First, no published sex-stratified efficacy or pharmacokinetic data from any retatrutide trial exist. Second, no data characterize the drug's behavior across the menstrual cycle or in women on hormonal contraception. Third, no menopausal-status stratification appears in current trial designs. Fourth, no PCOS-specific trial has been initiated. Fifth, the gallstone risk in women, who are already at twice the baseline risk, has not been reported separately. Sixth, the interaction between retatrutide and bone density has not been studied in postmenopausal women, where rapid weight loss can accelerate bone loss.

These gaps do not mean retatrutide will not work well for women. The Phase 2 enrollment of more than half women is a positive baseline. They mean that clinicians and patients will need to make individualized decisions with incomplete sex-specific information when approval eventually comes.